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There is increasing evidence of the efficacy of dose-dense therapy in the management of platinum-resistant/refractory ovarian cancer.
We report our experience of extended weekly carboplatin and paclitaxel in this population group. Twenty patients with platinum-
resistant/refractory ovarian cancer received carboplatin AUC 3 and paclitaxel 70mgm
 2 on day 1, 8, 15 q 4 weekly for six planned
cycles. Toxicity was assessed using Common Toxicity Criteria. Response was evaluated using radiological and CA125 criteria. Median
age was 61 years (range 40–74 years). Median number of prior therapies is three (range 1–8). Response rate was 60% by
radiological criteria (RECIST) and 76% by CA125 assessment. Grade 3 toxicities consisted of neutropenia (29% of patients) and
anaemia (5%). One patient experienced grade 4 neutropenia. No grade 3/4 thombocytopaenia was reported. Fatigue, nausea and
peripheral neuropathy were the most frequent non-hematological side effects. Median progression-free survival was 7.9 months and
overall survival was 13.3 months. The dynamics of response to dose-dense therapy were as rapid as with front-line therapy within the
same patient. This dose-dense regimen can be extended to at least 18 weekly cycles over 6 months and is well tolerated with high
response rates in heavily pre-treated, platinum-resistant ovarian cancer. It forms a highly active and tolerable cytotoxic scaffold to
which molecular-targeted therapies can be added in platinum-resistant ovarian cancer.
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Ovarian cancer is the leading cause of death from gynecologic
malignancies in the United Kingdom, and is the fourth most
common cause of cancer mortality in women (Piver et al, 1991).
Despite relatively high response rates to first-line platinum-based
therapies, the majority of patients with epithelial ovarian cancer
will experience disease relapse and will require further chemo-
therapy (Neijt et al, 1991). Several therapeutic options are available
and the decision as to which therapy to commence is dependent on
the time from last platinum chemotherapy to decision to treat,
known as the platinum-free interval (PFI) (Markman et al, 1991;
van der Burg et al, 1991). The PFI is a predictor of response not
only to second-line treatment with platinum-based chemotherapy
but also other active agents including the taxanes, topoisomerase I
inhibitors and anthracyclines (Eisenhauer et al, 1994). The
probability of response to platinum rechallenge increases with
the PFI, from 460% in patients relapsing 412 months since last
platinum therapy to below 10% in patients relapsing within 6
months (Markman et al, 1991). This entity of platinum-resistant
ovarian cancer, therefore, represents a different clinical scenario
with lower response rates between 10 and 15% to a range of
chemotherapy agents (Gordon et al, 2004; Mutch et al, 2007;
Ferrandina et al, 2008). However, there is increasing evidence that
by administering platinum in a ‘dose-dense’ manner involving
increased schedule frequency and increased dose intensity,
resistance can be overcome resulting in significant improvements
in response (van der Burg et al, 2005).
Thus, dose density refers to increasing dose frequency while the
dose per cycle and overall dose remains the same, thereby
increasing the dose intensity and shortening overall treatment
time (Simon and Norton, 2006). A number of different ‘dose-
dense’ carboplatin and paclitaxel regimens have been developed
for the treatment of recurrent ovarian cancer initially pioneered by
van der Burg et al (2002). They reported a response rate of 46%
in patients with a PFI of o4 months with weekly cisplatin
(50–70mgm
 2) and daily oral etoposide for 6 weekly cycles,
followed by maintenance oral etoposide. On the basis of finding
that weekly paclitaxel is also very active in platinum-resistant
disease, cisplatin and carboplatin have both been tolerably
combined with paclitaxel in short duration weekly schedules. de
Jongh et al (2002) and Van der Burg et al (2004) have reported on
weekly induction regimens of cisplatin 70mgm
 2 or carboplatin
AUC 4 with paclitaxel 90mgm
 2 for 6 weeks, followed by a return
to three weekly schedules. The authors report a response rate of
60% in platinum-resistant disease and progression-free survival of
8–11 months. However, if the dose-dense regimen is likely to be
the more active component of this regimen, there is a clear
rationale for continuing with weekly treatment rather than
reverting to a three weekly ‘maintenance’ schedule to which
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spatients had prior resistance. In practice, with these Rotterdam
regimens, the limitation in the dose-dense phase was toxicity.
Weekly dosing was also investigated earlier as part of the
‘Leuven’ dose regimen in which patients received continuous
weekly carboplatin AUC 4 and paclitaxel 90mgm
 2 on day 1 and 8
every 21days for 6 cycles (Cadron et al, 2007). The authors
reported a response rate of 38% in platinum-resistant patients with
a progression-free survival of 6.8 months and an overall survival of
8 months; these results were achieved with significant haemato-
logical toxicity. Havrilesky et al (2003) investigated weekly
carboplatin AUC 2 and paclitaxel 80mgm
 2 on day 1, 8 and 15
every 28 days until disease progression; thus not delivering dose-
dense platinum, as the platinum dose intensity in this regimen is
below that achieved with conventional schedules. For this regimen,
a median of 5.5 cycles (477 pulses) was administered with a similar
response rate of 38% reported in platinum-resistant patients and a
progression-free survival of 3.2 months, and an overall survival of
11 months. Although these studies suggest that weekly platinum
and taxane is an effective and well-tolerated approach in recurrent
ovarian cancer, neither the optimal schedule nor its duration has
been determined. This is important from the perspective not just
of response rate and maximal tolerated dose but also from the
perspective of potential durability of response in platinum-
resistant disease.
Here, we report our experience of dose dense weekly carboplatin
AUC 3 and paclitaxel 70mgm
 2 on day 1, 8, 15 q 4 weekly
administered in patients with heavily pre-treated platinum-
refractory and/or platinum-resistant ovarian cancer delivered for
an intended six blocks of therapy (18 cycles). It shows excellent
feasibility, tolerability and activity of this regime in a very difficult
patient group. The importance and novelty of this regime is its
feasibility and tolerability, and its potential for extended duration
therapy allows us to contemplate its use as a scaffold for the safe
integration of targeted therapies that may enhance the efficacy of
platinum rechallenge in a platinum-resistant scenario.
METHODS
This is a retrospective report of our experience of patients with a
diagnosis of epithelial ovarian cancer who had relapsed within a
platinum-resistant interval (p6 months) treated with dose-dense
carboplatin and paclitaxel. Carboplatin AUC 3 and paclitaxel
70mgm
 2 were administered on day 1, 8, 15 q 4 weekly, with the
intent to deliver six cycles of chemotherapy. Baseline CT imaging of
the chest, abdomen and pelvis was carried out prior to the
commencement of therapy and after every two cycles. Carboplatin
dose was calculated by ethylenediaminetetraacetic acid clearance.
Blood samples for full blood count, biochemistry, liver function tests
and serum CA125 test were taken prior to the commencement of
therapy and before each treatment. Patients were reviewed weekly
during treatment for safety assessment. All safety evaluations were
graded according to the NCI-CTC v5.0. Tumour response was
assessed after every two cycles with repeat CT chest, abdomen and
pelvis (RECIST criteria) and by CA125 (GCIG criteria) (Therasse
et al, 2000; Rustin, 2003). Data regarding the planned and delivered
weekly dose intensity of treatment, the overall treatment dose
delivered, toxicity and clinical outcome were collected.
Survival
Progression-free survival was measured from the date of first
treatment until either progression or death, the median OS was
defined as the period of time between the start of the treatment and
death and was censored at last follow-up. Survival curves were
generated using Kaplan–Meier methodology. Univariate survival
analyses were performed using the Kaplan–Meier method and log
rank tests. The relationship between subgroup variability and
response to treatment was analysed using either w
2-test or Fisher’s
exact test. Analysis was performed using SPSS software version
11.5 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patients
Twenty-three patients received dose-dense carboplatin/paclitaxel
between August 2006 and August 2008. Two patients were
excluded from analysis as one initially received cisplatin/etoposide
and one received two cycles of three weekly carboplatin
immediately prior to dose-dense therapy. All patients had
histologically proven epithelial ovarian cancer. All patients
had been treated earlier with carboplatin, and 18 (86%) patients
had previous conventional schedule taxane exposure. Patient
characteristics are shown in Table 1. The median age of the
evaluable patients was 61 years (range 40–74 years). The majority
of patients had a performance status of one (71%). Patients had
received an average of three (range 1–8) prior chemotherapeutic
regimens. Seven patients had platinum refractory disease following
front-line therapy. The mean PFI was 5.1 months (range 0.5–13.9
months). The mean taxane-free interval was 16.8 months (range
Table 1 Patient demographics (N¼21)
Patient demographics No of patients (%)
Age, years
Median 62
Range 41–75
WHO performance status
0 6 (29)
1 15 (71)
20
Tumour histology
Serous 19 (90)
Endometrioid 2 (10)
Mucinous 0
Clear cell 0
Tumour differentiation grade
10
2 4 (20)
3 16 (76)
Unknown 1 (5)
Number of prior chemotherapeutic regimens
1 7 (33)
2 6 (29)
3 5 (24)
X4 3 (14)
Time to relapse following last chemotherapy
Median 0.7 months
Range 0–6.7
Platinum-free interval, months
o61 2
X69
a
Taxane-free interval, months
o68
X61 1
No prior taxane 3
aSix patients relapsed within a platinum-resistant time period (o6 months) but
elected to delay treatment. Three patients received alternative chemotherapy for the
treatment of platinum-resistant disease.
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taxanes. All patients had relapsed within a platinum-resistant time
period and median time to relapse following platinum-based
therapy is 5.4 months (range 0–6.7). However, three patients
received treatment with non-platinum conventional chemotherapy
regimens (two received liposomal doxorubicin and one received
topotecan). Six patients symptomatically relapsed but were not
treated within 6 months either because of prolonged hospitalisa-
tion or because patients elected to delay treatment. The mean
treatment-free interval was 4.7 months (range 0.5–12.1 months).
An average of four blocks of dose-dense chemotherapy was
administered (range 1–6). The mean delivered dose intensity of
carboplatin per week was AUC 2.1 (range 0.5–2.25) against a
planned dose intensity of AUC 2.25. The median ratio of
carboplatin delivered vs planned dose was 95% (range 23–100).
Although no dose reduction in paclitaxel dosing was required, a
reduction in dose intensity was observed that was attributable to
dose delay. The mean delivered dose intensity of paclitaxel
was 50mgm
 2 per week (range 11.8–52.5) against a planned dose
intensity of 52.5mgm
 2 per week. The median ratio of paclitaxel
delivered vs planned dose was 91% (range 22–100).
Treatment efficacy
One patient was not assessed radiologically because of death prior
to assessment. Therefore, 20 patients were assessed for radiological
response. Confirmed partial tumour responses (RECIST) were
reported in 12 patients (60%). No complete responses were
reported. Four patients (20%) had stable disease and four (20%)
patients had progressive disease on treatment. All patients were
assessable for response by GCIG CA125 criteria. In all, 16 patients
(76%) achieved a response (Table 2).
The rate of decline in CA125 was assessed in 18 patients
compared with their rate of CA125 decline with first-line therapy.
Three patients commenced their first-line treatment in other
institutions and therefore their initial serum CA125 results were
not available. In patients receiving dose-dense therapy the median
half-life of serum CA125 was 16.5 days (range 0–41). The median
half-life of serum CA125 in this population at the time of front-line
treatment was longer at 18 days (range 0–42) (Table 3). Analysis of
patients whose CA125 half-life response to dose-dense therapy was
faster compared with front-line therapy revealed longer overall
survival (mean overall survival 20.2 months (95% CI 12.5–27.9) vs
8.8 months (95% CI 6.1–11.6), P¼0.018) but no difference in
progression-free survival (PFS). No association was observed
between CA125 half-life response to dose-dense therapy and PFI or
exposure to prior taxane therapy.
In the 16 patients who had been exposed to a taxane prior to
weekly carboplatin/paclitaxel, the CA125 response rate was 81%
and the radiologic response rate was 83%. There was no
correlation between the response rate to dose-dense therapy, by
either RECIST or GCIG criteria, and platinum-free interval,
taxane-free interval or treatment-free interval. At the time of
analysis, 11 patients had died. The median PFS was 7.9 months
(95% CI 7.59–8.35) (Figure 1). The median overall survival was
13.3 months (95% CI 7.81–18.79) (Figure 2).
Toxicity
Overall dose-dense carboplatin/paclitaxel was well tolerated
(Table 4). Six patients (29%) experienced grade 3 neutropenia
and one patient experienced grade 4 neutropenia. Two patients
required admission for neutropenic sepsis (10%). One patient
(5%) died as a result of sepsis. One patient experienced non-
neutropenic line sepsis (5%). One patient (5%) experienced
Table 2 Overall response rates to dose-dense carboplatin/paclitaxel
Response type No. of patients (%)
Radiologic response
Complete response 0
Partial response 12 (60)
Stable disease 4 (20)
Progressive disease 4 (20)
Table 3 Half-life of serum CA125 (days) during front-line chemotherapy
treatment and subsequent half-life with dose-dense chemotherapy
Subject
number
First-line chemotherapy:
half-life CA125 (days)
Dose-dense therapy:
half-life CA125 (days)
12 1 3 0
21 7 1 1
3 7.3 15
42 4 2 1
51 2 1 0
63 3 1 4
73 0 4 1
8— 1 8
9— R
10 37 R
11 20 33
12 13 R
13 R 37
14 — 30
15 12 12
16 17 23
17 42 35
18 10 10
19 19 23
20 12 28
21 19 18
Median 18 18
R¼Refractory.
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Figure 1 Kaplan–Meier curve for time to disease progression in patients
receiving dose-dense carboplatin and paclitaxel for platinum-resistant
ovarian cancer.
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ssymptomatic grade 3 anaemia. Importantly, grade 3/4 thrombo-
cytopenia or grade 4 anaemia were not observed.
Three patients required dose reductions secondary to neutro-
penia (14%), and one patient required two additional dose
reductions because of persistent neutropenia. Eight patients
required dose delays (38%), predominantly because of neutrope-
nia; however, we dose delayed patients rather than administer
granulocyte-colony stimulating factor (G-CSF). Only three patients
received G-CSF therapy (14%). G-CSF was administered 300mg
subcutaneously daily from day 3 to day 5. Three patients (14%)
experienced treatment delays because of Unit holidays.
The most common non-haematologic toxicity was grade 2
lethargy (33%). Two patients (10%) experienced grade 2 nausea
and vomiting. Three patients developed worsening of pre-existing
peripheral neuropathy leading to the cessation of treatment. Three
patients (14%) developed hypersensitivity reaction secondary to
carboplatin infusion. One patient was managed effectively with
pre-treatment with hydrocortisone 100mg intravenously and
chlorphenamine 10mg intravenously prior to carboplatin infusion.
Two patients ceased therapy because of hypersensitivity reactions
to carboplatin.
DISCUSSION
Several chemotherapeutic agents such as topotecan, gemcitabine,
liposomal doxorubicin, paclitaxel and etoposide have been used in
the treatment of platinum-resistant disease with unexciting
response rates in the range 10–15% in this patient group (Swisher
et al, 1997; Gordon et al, 2001). Our data show that the use of
extended dose-dense chemotherapy results in a response rate of
60% in this poor prognosis group, which is consistent with
previous published studies (de Jongh et al, 2002; Van der Burg
et al, 2004). Extended dose-dense therapy affords the opportunity
to effectively and tolerably treat conventionally platinum-resistant
patients with platinum again, and this study shows the feasibility
and tolerability of delivering up to six blocks (18 cycles) of this
treatment. This finding is of importance as platinum resistance
ultimately becomes the dominant problem for most patients with
ovarian cancer. The approach described here holds promise in that
it may be coupled to molecularly targeted therapies that can either
reverse acquired platinum resistance or enhance intrinsic platinum
sensitivity (Gordon et al, 2005; Schilder et al, 2005; Alvero et al,
2006; Appleton et al, 2007; Cannistra et al, 2007; Chien et al, 2007).
This approach may feasibly enhance efficacy to the point that
survival gains may become worthwhile. The regimen described in
this report, therefore, needs to be tested in a phase III setting
against the community standard for this population, pegylated
liposomal doxorubicin.
The mechanism by which dose-dense therapy induces responses
in patients with platinum-resistant disease is unclear. It is assumed
that a fixed proportional cell kill is achieved at shorter time
intervals, improving the overall impact of therapy, as it allows less
time and opportunity for the emergence and proliferation of
surviving cells. Furthermore, for S phase-specific drugs, more
frequent dosing may expose more cells to the drug during the
sensitive phase of the cell cycle. In addition, the use of weekly
paclitaxel may have additional anti-angiogenic effects when used
in a fractionated schedule (Belotti et al, 1996; Lau et al, 1999).
As outlined in the introduction, dose dense weekly schedules of
carboplatin and paclitaxel have been investigated by a number of
groups. These studies all differ in the dose intensity of carboplatin
and paclitaxel administered, the duration of dose-dense therapy
and the concurrent toxicity (Bolanos et al, 2001; Katsumata et al,
2001; Dunton, 2003; Havrilesky et al, 2003; Van der Burg et al,
2004; Kikuchi et al, 2005; Rose et al, 2005; Watanabe et al, 2005;
Cadron et al, 2007). However, only four of the nine identified
published studies enrolled patients with platinum-resistant disease
(Table 5). The results from our study (a response rate of 60% and a
PFS of 7.9 months in resistant or refractory disease) are
comparable with these previously reported data, although the
extended duration to six blocks (12 cycles total) has only been
shown in the Leuven study, which with an AUC 4/taxol 90mgm
 2
dosing could be delivered only as 2 weeks on and 1 week off, with
significant haematological toxicity, which therefore could make
integration of additional biotherapies difficult (Cadron et al, 2007).
We calculated the half-life of serum CA125, and have shown a
more rapid decline in CA125 after dose-dense therapy in platinum-
resistant disease compared with CA125 decline in front-line therapy
for individual patients. Furthermore, we have shown that patients
whose CA125 half-life response to dose-dense therapy was faster
compared with front-line therapy had an improved overall survival
when compared with those with a slower response. This is
consistent with previously published front-line studies, which
suggest that a shorter half-life is associated with improved prognosis
(Riedinger et al, 2008) (Mano et al,2 0 0 5 )( G a d d u c c iet al,2 0 0 4 ) .N o
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Figure 2 Kaplan–Meier curve for overall survival patients receiving
dose-dense carboplatin and paclitaxel for platinum-resistant ovarian cancer.
Table 4 Haematologic and non-haematologic toxicity of dose-dense
therapy
Grade no (%) 1 2 3 4
Anaemia 2 (10) 13 (62) 1 (5) 0
Neutropenia 4 (19) 5 (24) 6 (29) 1 (5)
Thrombocytopaenia 1 (5) 1 (5) 0 0
Lethargy 3 (14) 8 (38) 0 0
Nausea and vomiting 4 (19) 2 (10) 0 0
Oral mucositis 2 (10) 0 0 0
Arthralgia 1 (5) 1 (5) 0 0
Neurotoxicity 4 (19) 1 (5) 3 (14) 0
Renal toxicity 1 (5) 1 (5) 0 0
Otoxicity 1 (5) 1 (5) 0 0
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sstudy, however, has compared the decline in CA125 within patients
with subsequent treatments and the impact on clinical outcomes.
Although interesting, these results are based on a small sample size
and need confirmation in a larger patient population.
Although all the patients relapsed within a platinum-resistant
interval, treatment was delayed in nine patients such that these
patients did not receive a platinum regimen within 6 months.
Despite this, no differences were observed in response rates for
this group; however, it is possible that this subgroup may have
been more sensitive (resensitised) to platinum. A significant
minority of patients were not prior taxane exposed, which may
also have affected response to weekly therapy, although the small
sample size for this subgroup precluded statistical evidence for
this. Nevertheless, this is overall one of the largest reports of dose
dense weekly therapy in the resistant patient population and
further supports this approach to treatment in a difficult clinical
scenario. The ‘3 weeks on, 1 week off’ regimen described here
differs from those published earlier in its tolerability and,
therefore, potential for extension of therapy for at least 18 cycles,
over 24 weeks and possible use for treatment to progression
(which is not a standard approach in the United Kingdom, but may
be more acceptable in other countries).
We have shown that dose-dense carboplatin/paclitaxel regimen
can be administered safely with minimal toxicity in heavily pre-
treated platinum-resistant patients. In particular, we report a
negligible incidence of thrombocytopenia, the most important and
unaddressable dose limiting factor in this approach, and a low
incidence of grade 3/4 neutropenia (30%) in contrast to other
published studies. In particular, the study by Cadron et al (2007)
investigating carboplatin AUC 4 and paclitaxel 90mgm
 2 on day 1
and 8 every q 4 weekly reported an incidence of grade 3/4
neutropenia in 94% and thrombocytopenia in 25% of patients.
These toxicities would have curtailed the extended duration of the
use of this regimen and feasibility for integration with other
molecularly targeted therapies. Only one previous study examining
carboplatin AUC 2 and paclitaxel 80mgm
 2 reports a comparable
rate of neutropenia; however, the authors report a higher incidence
of grade 3/4 thrombocytopenia, and this study does not deliver
dose-dense platinum, indeed the dose intensity of platinum is less
than that of conventional therapy (Havrilesky et al, 2003).
Furthermore, we report a low incidence of anaemia compared
with the previous reports. We did observe a significant number of
dose delays because of neutropenia. As described above, we tended
to dose delay rather than administer G-CSF in myelosuppression
and this may have compromised the dose intensity of delivered
chemotherapy. In future studies, we propose the addition of G-CSF
300mg daily from day 3 to 5 to avoid neutropenia and maintain
dose intensity, and it will be interesting to observe whether this
will impact thrombocytopenia adversely. Interestingly, we also did
not observe a high rate of neurotoxicity despite the majority of
patients having had prior treatment with a taxane. Because of the
impact of neurotoxicity on patient quality of life, we plan to
formally assess neuropathy prior to and post dose-dense therapy
in future studies. A major limitation to the use of dose-dense
therapy is the development of hypersensitivity to platinum.
Previous studies do report hypersensitivity occurring in 6–23%
of patients treated. We report 14% of patients developing
hypersensitivity. Although one patient was effectively managed
with the use of hydrocortisone and anti-histamines, two patients
had to cease treatment. Desensitisation to platinum agents is an
active area of research and this may impact favourably on the
deliverability of platinum agents in the future.
This regimen is therefore a safe and effective regimen for
the management of platinum-resistant relapse, and efforts are
underway to explore this regimen in randomised clinical trials
against the current standard of care in platinum-resistant
ovarian cancer. Translational research efforts are also showing
that inhibition of several molecular targets can reverse
acquired clinical platinum resistance in vitro, and adaptations
of this regimen will be explored as a platinum scaffold to
incorporate inhibitors to such targets in order to maximise
clinical benefit to patients with platinum-resistant ovarian cancer
(Stronach et al, 2008).
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Table 5 Studies of weekly carboplatin and paclitaxel in platinum-resistant recurrent ovarian cancer
Study Regimen
Platinum
sensitivity N
RR
(%)
CR
(%)
PFS
(months)
OS
(months) Anaemia
Neutro-
paenia
Thrombo-
cytopaenia
Neuro-
toxicity Alopecia
Hyper-
sensitivity
Cadron et al T9 0m gm
 2 per week Total number 29 66 21 9 18 24 94 25 3 0 9
(2007) C AUC 4 per week o6 months 10 38 13 6.8 8
Days 1, 8, q 3 weekly 6–12 months 11 73 18 10.5 NR
6 courses 412 months 8 80 30 12.8 NR
2.6
Van der Burg T 90mgm
 2 per week Total number 62 74 24 11 NR 40 8 0 23
et al (2004) C AUC 4 per week o6 months 23 61 13
Days 1, 8, 15, 29, 36, 49 6–12 months 19 84 42
+6xTC q 3 weekly 412 months 20 80 20
Havrilesky T 80mgm
 2 per week Total number 29 83 55 11.5 11 32 14 0 0 21
et al (2003) C AUC 2 per week o6 months 8 38 13 3.2 11.4
Days 1, 8, 15 q 28 days until
progression/CR+8 courses
46 months 21 100 71 13.7
Katsumata T 80mgm
 2 per week Total number 45
(33)
67 39 61 15 21 6
et al (2001) C AUC 2 per week o6 months 11 55 (+ grade 2)
for 18 weeks 46 months 16 73
Current study T 70mgm
 2 per week Total number 21 60 0 7.9 13.3 5 30 0 15 NR 14
C AUC 3 per week Refractory 5 25 8.9 6.8
Days 1, 8, 15 q 4 weekly o6 months 7 25 5.5 —
4–6 courses 46 months 9 50 7.8 10.0
N¼number of patients; RR¼response rate; CR¼complete remission; PFS¼progression-free survival; OS¼overall survival; T¼paclitaxel; C¼carboplatin; NR¼not reached.
Toxicity is grade X3 and expressed in percentage. Adapted from Cadron et al (2007).
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